Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Non-Small Cell Lung Cancer Clear all
Completed Phase 2 Interventional

Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer

NCT00004126
View directory record Official record
Conditions
Lung Cancer
Interventions
oxaliplatin, paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
11
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

NCT01727076
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00085501
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, carboplatin, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
163
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Berkeley, California + 113 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function

NCT00002901
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer

NCT02581943
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment
Drug · Other · Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

NCT02408016
View directory record Official record
Conditions
Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, WT1 Positive
Interventions
Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Biological · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated Phase 1 Interventional

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer
Interventions
XMT-2056
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Celebration, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

NCT00039091
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Melanoma, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer
Interventions
ipilimumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

NCT01471197
View directory record Official record
Conditions
Lung Cancer - Non Small Cell
Interventions
Ipilimumab, Pemetrexed
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Greenbrae, California • Galesburg, Illinois • Quincy, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

NCT00216203
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pemetrexed, Cetuximab
Drug
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
11
States / cities
Galesburg, Illinois • Bloomington, Indiana • Elkhart, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Jul 23, 2026, 8:51 AM EDT
Completed No phase listed Observational

Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients

NCT00352391
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
Assessments
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
3
States / cities
Fort Gordon, Georgia • Johnstown, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jul 23, 2026, 8:51 AM EDT
Withdrawn Not applicable Interventional

Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer

NCT02250378
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Interventions
stereotactic radiosurgery, therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment
Radiation · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2015 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

NCT00024076
View directory record Official record
Conditions
Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
Interventions
radiofrequency ablation
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 23, 2026, 8:51 AM EDT
Withdrawn Phase 2 Interventional

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

NCT05935774
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Atezolizumab, Biopsy, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Trabedersen (OT-101)
Biological · Procedure · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

NCT00257608
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
bevacizumab, placebo, erlotinib HCl
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
177
States / cities
Mobile, Alabama • Fort Smith, Arizona • Scottsdale, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer

NCT00066768
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
suramin, docetaxel, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated Phase 2 Interventional Results available

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer

NCT02147990
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Rociletinib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
41
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas

NCT00019513
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorouracil, gemcitabine hydrochloride, leucovorin calcium
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2012 · Synced Jul 23, 2026, 8:51 AM EDT
Completed No phase listed Observational

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

NCT00003569
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions
cisplatin, dimesna, paclitaxel
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Jul 23, 2026, 8:51 AM EDT
Active, not recruiting Not applicable Interventional

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT01345851
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy, carboplatin, paclitaxel, stereotactic body radiation therapy
Radiation · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT00006347
View directory record Official record
Conditions
Lung Cancer
Interventions
indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Belleville, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer

NCT00079235
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
temsirolimus, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer

NCT02206334
View directory record Official record
Conditions
Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 8:51 AM EDT